Translationally Controlled Tumor-Associated Protein
Malgorzata Kloc, Jacek Kubiak, Mark Ghobrial

To cite this version:

HAL Id: inserm-00696213
https://www.hal.inserm.fr/inserm-00696213
Submitted on 14 May 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Translationally Controlled Tumor-Associated Protein

Malgorzata Kloc
The Methodist Hospital and The Methodist Hospital Research Institute
6670 Bertner Ave
Houston, Tx 77030

Jacek Z. Kubiak
CNRS UMR 6290, Institut Génétique et Développement de Rennes (IGDR),
Cell Cycle Group
Université Rennes 1, Faculty of Medicine,
Rennes, France

Rafik Mark Ghobrial
The Methodist Hospital
Department of Surgery
6550 Fannin st
Houston TX 77030

Translationally-Controlled Tumor-associated Protein (TCTP) has been discovered in 1983 in mouse erythroleukemia cells. Over the years it became evident that TCTP is an important player in a number of basic cell physiology events in cancer, embryo development, cell cycle, apoptosis, proliferation, growth, stress response, allergy, gene regulation and heat-shock response. However, despite the nearly three decades of research, we only start to understand the role of TCTP in physiology of animal and plant embryo development as well as in numerous pathologies through its participation in cell cycle, proliferation and growth regulation. The exact roles of TCTP in many complex
cellular processes still remain a mystery. One of the key questions in cancer research is
the role of TCTP in tumor reversion, the rare event leading to tumor regression and a
“miraculous” cure; is TCTP involved in gene regulation or rather modification of the
cytoskeleton of cancer cells during this process? It seems plausible that a novel type of
posttranslational modification of TCTP, namely SUMOylation by regulating its nuclear
localization and/or its association with the centrosomes, both featured in this issue, are
responsible for some of the TCTP functions in normal and cancer cells. From the
presented in this issue a very comprehensive and up to date reviews on TCTP functions it
clearly transpires that TCTP has a potential to be a crucial target for anti cancer therapies.
However, more research on the regulation of TCTP and its involvement in various
molecular and cellular pathways and its association with subcellular structures is needed
for the improvement of our understanding of this oncogene and development of novel
TCTP-targeted cancer therapies. We hope that our special issue on TCTP in BRI will
participate in stimulation of scientific research in this field.